Animal and Translational Models for CNS Drug Discovery combines the experience of academic, clinical and pharmaceutical neuroscientists in a unique collaborative approach to provide a greater understanding of the relevance of animal models of neuropsychiatric disorders and their role as translational tools for the discovery of CNS drugs being developed for the treatment of these disorders. The focus of this three-volume series of essays is to present a consensual picture of the translational value of animal models from leading experts actively involved in the use of animal models for understanding fundamental neurobiology of CNS disorders and the application of this knowledge to CNS drug discovery, and clinical investigators involved in clinical trials, drug development and eventual registration of novel pharmaceuticals.
Each volume of the Animal and Translational Models for CNS Drug Discovery series is dedicated to the development and use of animal models in key therapeutic areas in psychiatric, neurologic and reward deficit disorders. Each volume has introductory chapters expressing the view of the role and relevance of animal models for CNS drug discovery and development from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in relevant therapeutic areas and discusses the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery.
- Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process
- Critical evaluation of animal and translational models improving transition from drug discovery and clinical development
- Emphasizes what results mean to the overall drug discovery process
- Explores issues in clinical trial design and conductance in each therapeutic area
- Each volume is available for purchase individually.
Animal and Translational Models for CNS Drug Discovery combines the experience of academic, clinical and pharmaceutical neuroscientists in a unique collaborative approach to provide a greater understanding of the relevance of animal models of neuropsychiatric disorders and their role as translational tools for the discovery of CNS drugs being developed for the treatment of these disorders. The focus of this three-volume series of essays is to present a consensual picture of the translational value of animal models from leading experts actively involved in the use of animal models for understanding fundamental neurobiology of CNS disorders and the application of this knowledge to CNS drug discovery, and clinical investigators involved in clinical trials, drug development and eventual registration of novel pharmaceuticals. Each volume of the Animal and Translational Models for CNS Drug Discovery series is dedicated to the development and use of animal models in key therapeutic areas in psychiatric, neurologic and reward deficit disorders. Each volume has introductory chapters expressing the view of the role and relevance of animal models for CNS drug discovery and development from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in relevant therapeutic areas and discusses the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery.- Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process - Critical evaluation of animal and translational models improving transition from drug discovery and clinical development - Emphasizes what results mean to the overall drug discovery process - Explores issues in clinical trial design and conductance in each therapeutic area - Each volume is available for purchase individually.
Preface What Do You Mean by “Translational Research”? An Enquiry Through Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders
Robert A. McArthur1, Franco Borsini2,
1McArthur and Associates GmbH, Basel, Switzerland
2Sigma-tau S.p.A, Pomezia (Rome), Italy
References
1. Kline N.S. Clinical experience with iproniazid (marsilid). J Clin Exp Psychopathol. 1958;19(2, Suppl 1):72–78.
2. Selling L.S. Clinical study of a new tranquilizing drug; use of miltown (2-methyl-2-n-propyl-1,3-propanediol dicarbamate). JAMA. 1955;157(18):1594–1596.
3. Delay J., Deniker P. Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. J Clin Exp Psychopathol. 1955;16(2):104–112.
4. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711–715.
5. Hunter A.J. Animal and translational models of neurological disorders: An industrial perspective. In: McArthur R.A., Borsini F. Animal and Translational Models for CNS Drug Discovery: Neurologic Disorders. New York: Academic Press: Elsevier, 2008.
6. McArthur R., Borsini F. Animal models of depression in drug discovery: A historical perspective. Pharmacol Biochem Behav. 2006;84(3):436–452.
7. FDA (2004). Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. US Department of Health and Human Services, Food and Drug Administration, Washington, DC.
8. EMEA. The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future. London: The European Medicines Agency; 2005.
9. Nestler E.J., Gould E., Manji H., Buncan M., Duman R.S., Greshenfeld H.K., et al. Preclinical models: Status of basic research in depression. Biol Psychiatry. 2002;52(6):503–528.
10. Shekhar A., McCann U.D., Meaney M.J., Blanchard D.C., Davis M., Frey K.A., et al. Summary of a National Institute of Mental Health workshop: Developing animal models of anxiety disorders. Psychopharmacology (Berl). 2001;157(4):327–339.
11. Bromley E. A Collaborative Approach to Targeted Treatment Development for Schizophrenia: A Qualitative Evaluation of the NIMH-MATRICS Project. Schizophr Bull. 2005;31(4):954–961.
12. Winsky L., Brady L. Perspective on the status of preclinical models for psychiatric disorders. Drug Discov Today: Disease Models. 2005;2(4):279–283.
13. Stables J.P., Bertram E., Dudek F.E., Holmes G., Mathern G., Pitkanen A., et al. Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: Summary of the NIH/NINDS/AES models II workshop. Epilepsia. 2003;44(12):1472–1478.
14. Stables J.P., Bertram E.H., White H.S., Coulter D.A., Dichter M.A., Jacobs M.P., et al. Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia. 2002;43(11):1410–1420.
15. McCann D.J., Acri J.B., Vocci F.J. Drug discovery and development for reward disorders. In: McArthur R.A., Borsini F. Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders. New York: Academic Press: Elsevier, 2008.
16. Rocha B., Bergman J., Comer S.D., Haney M., Spealman R.D. Development of medications for heroin and cocaine addiction and Regulatory aspects of abuse liability testing. In: McArthur R.A., Borsini F. Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders. New York: Academic Press: Elsevier, 2008.
17. Winsky L., Driscoll J., Brady L. Drug discovery and development initiatives at the National Institute of Mental Health: From cell-based systems to Proof-of-Concept. In: McArthur R.A., Borsini F. Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders. New York: Academic Press: Elsevier, 2008.
18. Jones D.N.C., Gartlon J.E., Minassian A., Perry W., Geyer M.A. Developing new drugs for schizophrenia: From animals to the clinic. In: McArthur R.A., Borsini F. Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders. New York: Academic Press: Elsevier, 2008.
19. McEvoy J.P., Freudenreich O. Issues in the design and conductance of clinical trials. In: McArthur R.A., Borsini F. Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders. New York: Academic Press: Elsevier, 2008.
20. Schuster D.P., Powers W.J. Translational and Experimental Clinical Research. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
21. Mankoff S.P., Brander C., Ferrone S., Marincola F.M. Lost in translation: Obstacles to translational medicine. J Transl Med. 2004;2(1):14.
22. Littman B.H., Williams S.A. The ultimate model organism: Progress in experimental medicine. Nat Rev Drug Discov. 2005;4(8):631–638.
23. Robbins T.W. Homology in behavioural pharmacology: An approach to animal models of human cognition. Behav Pharmacol. 1998;9(7):509–519.
24. Millan M.J. The discovery and development of pharmacotherapy for psychiatric disorders: A critical survey of animal and translational models, and perspectives for their improvement. In: McArthur R.A., Borsini F. Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders. New York: Academic Press: Elsevier, 2008.
25. Domenjoz R. From DDT to imipramine. In: Healey D., ed. The Psychopharmacologists III: Interviews with David Healy. London: Arnold; 2000:93–118.
26. Kuhn R. From imipramine to levoprotiline: the discovery of antidepressants. In: Healey D., ed. The Psychopharmacologists II: Interviews with David Healy. London: Arnold; 1999:93–118.
27. Janssen P. From haloperidol to risperidone. In: Healy D., ed. The Psychopharmacologists II: Interviews by David Healy. London: Arnold; 1999:39–70.
28. Almond S., O’Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics. 2000;17(4):383–389.
29. Gasquet I., Gury C., Tcherny-Lessenot S., Quesnot A., Gaudebout P. Patterns of prescription of four major antipsychotics: A retrospective study based on medical records of psychiatric inpatients. Pharmacoepidemiol Drug Safety. 2005;14(11):805–811.
30. Pizzo P. (2002). Letter from the Dean, Stanford Medicine Magazine. Stanford University School of Medicine.
31. Lerman C., LeSage M.G., Perkins K.A., O’Malley S.S., Siegel S.J., Benowitz N.L., et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov. 2007;6(9):746–762.
32. Horig H., Pullman W. From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference. J Transl Med. 2004;2(1):44.
33. Beckmann N., Kneuer R., Gremlich H.U., Karmouty-Quintana H., Ble F.X., Muller M. In vivo mouse imaging and spectroscopy in drug discovery. NMR Biomed. 2007;20(3):154–185.
34. Risterucci C., Jeanneau K., Schoppenthau S., Bielser T., Kunnecke B., von Kienlin M., et al. Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia. Psychopharmacology (Berl). 2005;180(4):724–734.
35. Tamminga C.A., Lahti A.C., Medoff D.R., Gao X.-M., Holcomb H.H. Evaluating Glutamatergic Transmission in Schizophrenia. Ann NY Acad Sci. 2003;1003(1):113–118.
36. Shah Y.B., Marsden C.A. The application of functional magnetic resonance imaging to neuropharmacology. Curr Opin Pharmacol. 2004;4(5):517–521.
37. Robbins T.W. Synthesizing schizophrenia: A bottom-up, symptomatic approach. Schizophr Bull. 2005;31(4):854–864.
38. Porrino L.J., Daunais J.B., Rogers G.A., Hampson R.E., Deadwyler S.A. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol. 2005;3(9):e299.
39. McKinney W.T.J., Bunney W.E.J. Animal model of depression I: Review of evidence: implications for research. Arch Gen Psychiatry. 1969;21(2):240–248.
40. American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edition. American Psychiatric Association, Washington, DC.
41. World Health Organization. (2007). International Statistical Classification of Diseases, 10th Revision, 2nd Edition. World Health Organization, Geneva.
42. Silverstone P.H. Is anhedonia a good measure of depression? Acta Psychiatr Scand. 1991;83(4):249–250.
43. Hyman S.E. Can neuroscience be integrated into the DSM-V? Nat Rev Neurosci. 2007;8(9):725–732.
44. Kupfer D.J., First M.B., Regier D.A. A Research Agenda for DSM-V. Washington, DC: American Psychiatric Association, 2002.
45. Eisenberg D.T., Mackillop J., Modi M., Beauchemin J., Dang D., Lisman S.A., et al. Examining impulsivity as an endophenotype using a behavioral approach: A DRD2 TaqI A and DRD4 48-bp VNTR association study. Behav Brain Funct. 2007;3:2.
46. Hasler G.,...
| Erscheint lt. Verlag | 27.11.2008 |
|---|---|
| Sprache | englisch |
| Themenwelt | Literatur |
| Sachbuch/Ratgeber | |
| Geisteswissenschaften ► Psychologie ► Allgemeine Psychologie | |
| Geisteswissenschaften ► Sprach- / Literaturwissenschaft ► Sprachwissenschaft | |
| Medizin / Pharmazie ► Gesundheitsfachberufe | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Neurologie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie | |
| Naturwissenschaften ► Biologie ► Zoologie | |
| Naturwissenschaften ► Chemie | |
| Technik | |
| ISBN-10 | 0-08-092041-1 / 0080920411 |
| ISBN-13 | 978-0-08-092041-2 / 9780080920412 |
| Haben Sie eine Frage zum Produkt? |
PDF (Adobe DRM)Größe: 9,2 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
EPUB (Adobe DRM)Größe: 7,6 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
